Seppic has expanded its injectable surfactant portfolio with MONTANOX 20 HPB, which has debuted at this year's CPHI Milan.
The new excipient, according to the company is of high purity and is specifically designed to be incorporated into biological drugs.
This release follows the significant increase in demand for biologics in recent years, with the biologics market expected to grow at an annual rate of 10% in the coming years.1,2
To ensure biopharmaceuticals are fully efficacious, biological active ingredients must be stable within a solution — which can be achieved by the use of specific excipients.
Montanox 20 HPB is a polysorbate 20 suitable for use with sensitive biologics, as it has stricter specifications on fatty acid distribution to minimise the risk of active ingredient degradation.
The excipient product is GMP compliant, as well as aligning with the current Pharmacopeias in force.
Seppic's Injectables Market Manager, Hocine Nouari, commented: “The launch of this new, high value-added HPB reference is a significant innovation in Seppic's injectable surfactants sector. It marks our determination to develop ever more specific and qualitative ingredients for rapidly expanding markets such as the biologics market.”
References
1 https://www.businesswire.com/news/home/20210528005373/en/Global-Biologics-Market-2021-to-2028---Size-Share-Analysis-Report---ResearchAndMarkets.com
2 https://www.grandviewresearch.com/industry-analysis/biologics-market
